Snapshot A 26-year-old female patient presents to her physician due to chronic fatigue. Upon further questioning, the patient reports that she no longer enjoys seeing her younger cousins, something that has brought her great happiness in the past. She has lost 10 pounds over the past month, which she attributes to her decreased appetite. She says that it has been very difficult for her to concentrate lately, is unable to sleep, and finds it difficult to get out of bed due to feeling "drained." (Major depressive disorder) Overview Neurotransmitter Site of Synthesis ↑ in Disease ↓ in Disease Comments Acetylcholine (ACh) Basal nucleus of Meynert Parkinson's disease Alzheimer's disease Huntington's disease Involved in learning and memory in the central nervous system (CNS) All motor neurons to skeletal muscles use ACh All preganglionic neurons use ACh at the ganglion of the parasympathetic and sympathetic system Postganglionic parasympathetic fibers use ACh Presynaptic neurons of the adrenal medulla use ACh Dopamine Ventral tegmentum Substantia Nigra pars compacta Arcuate nucleus (tubuloinfundibular pathway) Huntington's disease Schizophrenia Parkinson's disease Depression Also known as prolactin-inhibiting factor antipsychotics (dopamine antagonists) can lead to increased prolactin secretion → galactorrhea and amenorrhea Involved in movement and working memory Involved in addiction γ-Aminobutyric acid (GABA) Nucleus accumbens - Huntington's disease Anxiety Major inhibitory neurotransmitter of the brain glycine is the major inhibitory neurotransmitter in the spinal cord Benzodiazepines act on GABA receptors to enhance GABA activity Baclofen is a GABA B receptor agonist that relieves spasticity Norepinephrine (NE) Locus ceruleus Anxiety Depression Involved in mood control and sleep-wake cycle Postganglionic sympathetic fibers release NE important for maintaining blood pressure Serotonin (5-HT) Raphe nucleus - Depression Anxiety Serotonin re-uptake inhibitors (SSRIs) are effective in treating depression, anxiety disorders, obsessive compulsive disorder Serotonin syndrome secondary to high levels of sertonin (e.g., MAO inhibitor + SSRI)
QUESTIONS 1 of 3 1 2 3 Previous Next Lab Values Blood Hematologic Cerebrospinal Sweat, Urine, and BMI Blood, Plasma, Serum Reference Range ALT 8-20 U/L Amylase, serum 25-125 U/L AST 8-20 U/L Bilirubin, serum (adult) Total // Direct 0.1-1.0 mg/dL // 0.0-0.3 mg/dL Calcium, serum (Ca2+) 8.4-10.2 mg/dL Cholesterol, serum Rec: < 200 mg/dL Cortisol, serum 0800 h: 5-23 μg/dL //1600 h: 3-15 μg/dL 2000 h: ≤ 50% of 0800 h Creatine kinase, serum Male: 25-90 U/LFemale: 10-70 U/L Creatinine, serum 0.6-1.2 mg/dL Electrolytes, serum Sodium (Na+) 136-145 mEq/L Chloride (Cl-) 95-105 mEq/L Potassium (K+) 3.5-5.0 mEq/L Bicarbonate (HCO3-) 22-28 mEq/L Magnesium (Mg2+) 1.5-2.0 mEq/L Estriol, total, serum (in pregnancy) 24-28 wks // 32-36 wks 30-170 ng/mL // 60-280 ng/mL 28-32 wk // 36-40 wks 40-220 ng/mL // 80-350 ng/mL Ferritin, serum Male: 15-200 ng/mLFemale: 12-150 ng/mL Follicle-stimulating hormone, serum/plasma Male: 4-25 mIU/mL Female: premenopause: 4-30 mIU/mL midcycle peak: 10-90 mIU/mL postmenopause: 40-250 pH 7.35-7.45 PCO2 33-45 mmHg PO2 75-105 mmHg Glucose, serum Fasting: 70-110 mg/dL2-h postprandial:<120 mg/dL Growth hormone - arginine stimulation Fasting: <5 ng/mLProvocative stimuli: > 7ng/mL Immunoglobulins, serum IgA 76-390 mg/dL IgE 0-380 IU/mL IgG 650-1500 mg/dL IgM 40-345 mg/dL Iron 50-170 μg/dL Lactate dehydrogenase, serum 45-90 U/L Luteinizing hormone, serum/plasma Male: 6-23 mIU/mL Female: follicular phase: 5-30 mIU/mL midcycle: 75-150 mIU/mL postmenopause 30-200 mIU/mL Osmolality, serum 275-295 mOsmol/kd H2O Parathyroid hormone, serume, N-terminal 230-630 pg/mL Phosphatase (alkaline), serum (p-NPP at 30° C) 20-70 U/L Phosphorus (inorganic), serum 3.0-4.5 mg/dL Prolactin, serum (hPRL) < 20 ng/mL Proteins, serum Total (recumbent) 6.0-7.8 g/dL Albumin 3.5-5.5 g/dL Globulin 2.3-3.5 g/dL Thyroid-stimulating hormone, serum or plasma .5-5.0 μU/mL Thyroidal iodine (123I) uptake 8%-30% of administered dose/24h Thyroxine (T4), serum 5-12 μg/dL Triglycerides, serum 35-160 mg/dL Triiodothyronine (T3), serum (RIA) 115-190 ng/dL Triiodothyronine (T3) resin uptake 25%-35% Urea nitrogen, serum 7-18 mg/dL Uric acid, serum 3.0-8.2 mg/dL Hematologic Reference Range Bleeding time 2-7 minutes Erythrocyte count Male: 4.3-5.9 million/mm3Female: 3.5-5.5 million mm3 Erythrocyte sedimentation rate (Westergren) Male: 0-15 mm/hFemale: 0-20 mm/h Hematocrit Male: 41%-53%Female: 36%-46% Hemoglobin A1c ≤ 6 % Hemoglobin, blood Male: 13.5-17.5 g/dLFemale: 12.0-16.0 g/dL Hemoglobin, plasma 1-4 mg/dL Leukocyte count and differential Leukocyte count 4,500-11,000/mm3 Segmented neutrophils 54%-62% Bands 3%-5% Eosinophils 1%-3% Basophils 0%-0.75% Lymphocytes 25%-33% Monocytes 3%-7% Mean corpuscular hemoglobin 25.4-34.6 pg/cell Mean corpuscular hemoglobin concentration 31%-36% Hb/cell Mean corpuscular volume 80-100 μm3 Partial thromboplastin time (activated) 25-40 seconds Platelet count 150,000-400,000/mm3 Prothrombin time 11-15 seconds Reticulocyte count 0.5%-1.5% of red cells Thrombin time < 2 seconds deviation from control Volume Plasma Male: 25-43 mL/kgFemale: 28-45 mL/kg Red cell Male: 20-36 mL/kgFemale: 19-31 mL/kg Cerebrospinal Fluid Reference Range Cell count 0-5/mm3 Chloride 118-132 mEq/L Gamma globulin 3%-12% total proteins Glucose 40-70 mg/dL Pressure 70-180 mm H2O Proteins, total < 40 mg/dL Sweat Reference Range Chloride 0-35 mmol/L Urine Calcium 100-300 mg/24 h Chloride Varies with intake Creatinine clearance Male: 97-137 mL/minFemale: 88-128 mL/min Estriol, total (in pregnancy) 30 wks 6-18 mg/24 h 35 wks 9-28 mg/24 h 40 wks 13-42 mg/24 h 17-Hydroxycorticosteroids Male: 3.0-10.0 mg/24 hFemale: 2.0-8.0 mg/24 h 17-Ketosteroids, total Male: 8-20 mg/24 hFemale: 6-15 mg/24 h Osmolality 50-1400 mOsmol/kg H2O Oxalate 8-40 μg/mL Potassium Varies with diet Proteins, total < 150 mg/24 h Sodium Varies with diet Uric acid Varies with diet Body Mass Index (BMI) Adult: 19-25 kg/m2 Calculator ( ) xy AC 7 8 9 ÷ 4 5 6 × 1 2 3 - 0 . = + Sorry, this question is for PEAK Premium Subscribers only Upgrade to PEAK You have 100% on this question. Just skip this one for now. Take This Question Anyway (M1.NE.73) A 31-year-old man presents to his primary care physician endorsing three months of decreased sleep. He reports an inability to fall asleep; although once asleep, he generally sleeps through the night and wakes up at a desired time. He has instituted sleep hygiene measures, but this has not helped. He has not felt anxious or depressed and is otherwise healthy. You prescribe him a medication that has the potential side effect of priapism. From which of the following locations is the neurotransmitter affected by this medication released? Review Topic | Tested Concept QID: 106587 Type & Select Correct Answer 1 Substantia nigra 10% (11/110) 2 Raphe nucleus 50% (55/110) 3 Locus ceruleus 15% (16/110) 4 Nucleus accumbens 15% (16/110) 5 Posterior pituitary 5% (6/110) M1 Question Complexity B Question Importance Select Answer to see Preferred Response SUBMIT RESPONSE 2 Sorry, this question is for PEAK Premium Subscribers only Upgrade to PEAK
All Videos (1) Podcasts (0) Login to View Community Videos Login to View Community Videos Neurotransmitters types Keshav Mudgal Neurology - Neurotransmitters 9/30/2015 53 views